Company Overview and News
Meridian Energy has axed "unjustifiable" prompt payment discounts, effectively cutting its power prices to all customers by the 10-to-16 per cent discount it has traditionally offered to those who pay their electricity bills on time.
CEN COENF CEN MEZ COENY
New Zealand power generators pocketed an extra $5.4 billion on profits from 2010 to 2016 over and above what they would have if the wholesale electricity market was truly competitive, according to a report by a University of Auckland economist.
GNE GNE MEZ GEL
New Zealand shares rose, joining a regional rally on optimism over US-China trade relations. Fonterra Cooperative Group's first annual loss dominated local headlines.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF GNE CEN KMD GEL SML KTHDY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY ANZFF GNE MEZ
New Zealand shares fell for a third session, taking their weekly decline to 2.3 per cent, as investors cashed in some of August's gains in what was a strong month for the local market. Tourism Holdings and a2 Milk Co declined.
WYN AIR FCREY NZTCF RYM ACKDF ANZFY AUKNY AIZ KMD SKT SYKWF SKKTY KMD SML KTHDY AIA FBU RHCGF SPKKY NZTCY SPK FRCEF AIA FBU THL ANZLY RYHTY OHE ANZFF MEZ
New Zealand shares hit another record amidst a slew of earnings, with Trade Me Group and A2 Milk Co gaining on their annual accounts while Fletcher Building dropped.
TME TRMEF FBU WBC FCREY SPKKY NZTCY SPK NZTCF WEBNF WBK FRCEF WBC PPSHY FBU TME TDMEY MEZ
It's four years since the National Government completed a raft of partial privatisations raising $4.7 billion which was ostensibly to be used to towards funding new infrastructure.
CEN AIR ANZFY COENY AIZ COENF GNE ANZLY CEN ANZFF GNE MEZ GEL
The record-breaking New Zealand sharemarket is poised to take in the good, the bad and the fair-to-middling tomorrow when a slew of results from the country's top corporates are due.
FBU FBU ANZLY AIR FCREY ANZFF ANZFY FRCEF MEZ AIZ
New Zealand shares rose as investors took stock in a brief lull to the domestic corporate earnings season, with Skellerup Holdings extending yesterday's gain to break a new record.
CEN AIR NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF GNE AOTUF SKC PPSHY CEN SNZ SKL GEL AIA RHCGF SPKKY NZTCY SPK COENY AIA THL ANZLY RYHTY SKLUY ANZFF GNE MEZ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ASX:MEZ / MERIDIAN ENERGY LIMITED on message board site Silicon Investor.
|GameZnFlix Inc. New||GameZnFlix Inc. New||GameZnFlix Inc. New||Gameznflix Inc (GZFX)||Gameznflix Inc (GZFX)||Gameznflix Inc (GZFX)|
|Gomez Advisors (GOMZ)||Gomez Advisors (GOMZ)||Gomez Advisors (GOMZ)|